Pressmeddelande

BioStock: Elicera’s CEO: “One of the biggest milestones in our history”

Cision Publicerad: 12 Nov 12:27

Elicera Therapeutics has officially entered clinical trials with its drug candidate ELC-301. This CAR T-cell therapy is being evaluated in a phase I/IIa study on patients with hard-to-treat B-cell lymphomas, mantle cell lymphoma, or indolent lymphomas where standard treatments have failed. By launching the CARMA study, Elicera takes a significant step forward, advancing cancer treatment and positioning itself as a pioneer in Swedish CAR T-cell research.

Read the interview at biostock.se:

https://www.biostock.se/en/2024/11/eliceras-ceo-one-of-the-biggest-milestones-in-our-history/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Nyheter om Elicera Therapeutics

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!